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Introduction {#sec1-1}
============

Neural tube defects (NTDs) are a series of severe congenital malformations in the central nervous system that result from defective neural tube closure during embryogenesis. NTDs are the second most common birth defect in the world, affecting 0.5--2 in every 1000 pregnancies (Greene et al., 2009). In China, the incidence of NTDs is high, particularly in Shanxi Province (Liu et al., 2016).

The aetiologies of NTDs are complicated, and both genetic and environmental factors have been implicated (Chen et al., 2010; Wilde et al., 2014). Over 100 candidate genes have been investigated for their association with NTDs (Boyles et al., 2005; Copp and Greene, 2010), but the mechanisms of neural tube defects are still unclear. Some studies have demonstrated that advanced glycation end products (Li et al., 2014a) or polycyclic aromatic hydrocarbon-DNA adducts (Yuan et al., 2013; Yi et al., 2015) mediate DNA damage that may be a significant contributor to neural tube defects. Furthermore, several DNA repair genes such as *APEX1*, *XRCC1*, *XRCC3*, *XPD*, *hOGG1*, *hMLH1*, and *hMSH2* have been reported to be associated with NTDs (Olshan et al., 2005; Au et al., 2010; Liu et al., 2012). However, O6-methylguanine DNA methyltransferase (MGMT), a DNA repair enzyme, which includes the simplest of the human DNA repair responses, is less frequently reported in NTDs. In fact, only one study has reported this (Tran et al., 2012). MGMT has been reported in other congenital malformations; several SNPs within MGMT were examined for an association with increased risk of congenital heart disease (Chowdhury et al., 2012; Li et al., 2014b) and Beckwith-Wiedemann syndrome (Paganini et al., 2015). Prior studies have reported that lower MGMT expression levels are linked to both tumourigenesis and teratogenic drug susceptibility (Glassner et al., 1999; Kitajima et al., 2003; Bobola et al., 2007), and a loss of MGMT expression is almost entirely associated with the methylation of CpG islands in the promoter region of the MGMT gene (Minoo, 2013; Mokhtar et al., 2014; Toffolatti et al., 2014). Therefore, this study focused on alterations in MGMT expression or promoter methylation in an animal model of NTD.

Maternal all-trans retinoic acid (ATRA) administration has long been used to induce a rat model of foetal spina bifida aperta (SBA) for the study of NTDs (Diez-Pardo et al., 1995). Our previous studies used this model to explore the pathogenesis of SBA (Li et al., 2012; Wu et al., 2013), and we verified that this rat SBA model is similar to human NTDs (Cai et al., 2007). Because the role of MGMT in ATRA-induced SBA in rats has not been reported, the rat model of SBA was used in this study to investigate the expression patterns of MGMT in different embryonic stages.

Therefore, this study examined the potential influence of the expression pattern of MGMT in spinal tissues on neural tube closure in an ATRA-induced model of SBA in rats. We then investigated DNA methylation levels of the MGMT promoter to determine whether the expression of MGMT is controlled by methylation.

Materials and Methods {#sec1-2}
=====================

Animals and spinal cord preparation {#sec2-1}
-----------------------------------

Specific-pathogen-free female Wistar rats aged 10--12 weeks old and weighing 230--260 g were purchased from Liaoning Changsheng Biotechnology Co., Ltd., China \[animal license number: SCXK (Liao) 2015-0001\]. Forty-four pregnant rats were divided into two treatment groups. Rats in the SBA group (*n* = 23) received a single intragastric administration of ATRA (Sigma, St. Louis, MO, USA; 4% wt/vol in olive oil; 140 mg/kg body) *via* a single gavage feeding on embryonic day 10 (E10), as previously described (Danzer et al., 2005). Rats in the normal control group (*n* = 21) received the same amount of olive oil on the same embryonic day. All pregnant rats were euthanized with an overdose injection of 10% chloral hydrate on E11, E12, E14, E16, and E18; the foetuses were harvested immediately thereafter. Foetuses without defects in the ATRA treatment group were considered as the ATRA-treated control group for further analysis. For each analysis, spinal cords (from the inferior margin of the forelimb bud to the tail bud) were obtained from each group at each embryonic day from at least three dams. All experimental procedures were approved by the Animal Ethics Committee, Shengjing Hospital, China Medical University, China (approval No. 2015PS264K) on October 13, 2015.

Western blot assay {#sec2-2}
------------------

After samples were collected, spinal cord tissues were lysed with ice-cold radio-immunoprecipitation assay buffer (Solarbio, R0010, Beijing, China) supplemented with 1 mM of phenylmethanesulfonyl fluoride and centrifuged, and the supernatant was collected. Protein quantification was determined by the bicinchoninic acid assay. After separation on 13% sodium dodecyl sulphate-polyacrylamide gels, proteins were electrophoretically transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membrane was blocked with 5% bovine serum albumin in Tris-buffered saline containing 0.1% Tween-20 (TBST) at room temperature for 2 hours. Membranes were incubated with the primary antibody, mouse anti-γ-H2A.X (ab26350, Abcam Incorporation, Cambridge, MA, USA), at 1:1000 dilution in TBST + 1% bovine serum albumin overnight at 4°C, and then incubated with the secondary antibody, a goat anti-mouse horseradish peroxidase-conjugated antibody (ZDR-5307, ZSGB-bio, Beijing, China), at 1:2000 dilution at room temperature for 2 hours. Enhanced chemiluminescence (Millipore) was used to visualize the protein signals. The relative optical densities of the bands were measured using ImageJ software (NIH, Bethesda, MD, USA), with β-actin serving as the loading control.

Real time-polymerase chain reaction (RT-PCR) analysis {#sec2-3}
-----------------------------------------------------

For mRNA expression analysis, total RNA was extracted from the spinal cords of five SBA foetuses and five control foetuses at each time point using TRIzol reagent (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. The RNA was quantified, and samples with an A~260\ nm~/A~280\ nm~ ratio of less than 1.8 were discarded.

To perform the mRNA expression analysis, 1 μg of total RNA was transferred into cDNA using a Prime Script RT Reagent Kit with gDNA Eraser (TaKaRa Bio, Shiga, Japan). Reaction solutions (20 μL) were incubated at 37°C for 15 minutes, followed by 85°C for 5 seconds. Diluted cDNA (1:5) was subjected to RT-PCR using a Light Cycler 480 SYBR Green I Master (Roche Diagnostics GmbH, Mannheim, Germany). The 20 μL reaction solution contained 10 μL of 2 × SYBR Green Master Mix, 2 μL of the cDNA template, 1 μL of each primer (5 μM), 0.4 μL of ROXII, and 5.6 μL of RNase-free water. Primers for MGMT were designed using Primer Premier 5 software (Premier Company, Canada). Experiments were performed in triplicate on a PCR thermal cycler (Light Cycler 480 Real-time PCR System, Roche Diagnostics GmbH) as follows: pre-denaturation at 95°C for 30 seconds, 45 cycles at 95°C for 5 seconds and 60°C for 20 seconds. Expression values were normalized to the geometric means of the housekeeping genes β-actin and GAPDH. Relative mRNA expression levels were calculated using the 2^--ΔΔCT^ method (Livak and Schmittgen, 2001). Detailed information for the primers used in this assay is included in **[Table 1](#T1){ref-type="table"}**.
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Real time-polymerase chain reaction primers and products
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Bisulfite treatment and DNA methylation analysis {#sec2-4}
------------------------------------------------

After the mRNA expression analysis, genomic DNA was extracted from spinal cords using the DNeasy Blood & Tissue Kit (QIAGEN, Hilden, Germany). Briefly, homogenized tissue was incubated in lysis buffer containing proteinase K and RNase at 56°C for 45 minutes. The DNA was eluted with TE buffer, then quantified using a NanoDrop ND-1000 (Thermo Scientific, Thermo Fisher Scientific, Waltham, MA, USA), and samples with an A~260\ nm~/A~280\ nm~ ratio outside the range of 1.8--2.0 were discarded. The DNA was stored at −20°C for a subsequent experiment.

After genomic DNA extraction, 2 μg of genomic DNA from each sample was bisulfite-treated with the EpiTect Bisulfite Kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. Treated DNA was stored at −80°C until use.

Bisulfite sequencing PCR was used to investigate the methylation pattern of the MGMT promoter. The target region was a 283 bp section of the rat MGMT promoter CpG island containing 17 CpG sites. The bisulfite-treated DNA was then amplified by PCR. The primers were designed using Methprimer (Li and Dahiya, 2002). Bisulfite sequencing PCR primer sequences are shown in **[Table 2](#T2){ref-type="table"}**. The PCR cycles were as follows: pre-denaturation at 94°C for 5 minutes, denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 45 seconds. These steps were repeated for 34 cycles, followed by a final extension at 72°C for 7 minutes. The PCR products were run on 1.5% agarose gels with 10% ethidium bromide and visualized with ultraviolet light. The PCR products were purified using the QIAquick Gel Extraction Kit (Qiagen GmbH) and cloned into the pGEM-T vector (Promega, Madison, WI, USA). A minimum of five white colonies were selected for each allele using lacZ blue-white selection screening; automated sequencing was then performed using M13 primers. The methylation pattern of each allele was analyzed with the online software QUMA (<http://quma.cdb.riken.jp/>) (Kumaki et al., 2008).

###### 

BSP primers and products
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Statistical analysis {#sec2-5}
--------------------

All values are shown as the mean ± SEM. All statistical analyses were performed using GraphPad Prism version 5 software (GraphPad Software, Inc., La Jolla, CA, USA). Student's *t*-test and one-way analysis of variance followed by Fisher's least significant difference *post hoc* test were used for single and multiple comparisons, respectively. For all statistical analyses performed, *P* values less than 0.05 were considered significantly different.

Results {#sec1-3}
=======

ATRA induces NTDs in rats {#sec2-6}
-------------------------

In the ATRA-treated group, 192 live embryos were harvested from 23 pregnant rats from E11, E12, E14, E16, and E18. There was approximately 11% incidence of dead or absorbed foetuses. SBA (61%; 118 of 192 live embryos) embryos were determined by gross morphologic examination under a stereomicroscope. Embryos with SBA were considered as the SBA group (*n* = 118). Embryos without defects were considered as the ATRA-treated control group (*n* = 62). The normal control group consisted of 167 embryos harvested from 21 olive oil-treated dams.

DNA damage analysis {#sec2-7}
-------------------

To determine DNA damage, we assessed the γ-H2A.X (phosphorylated H2A.X on Ser139) level in foetuses with SBA. H2A.X is rapidly phosphorylated on serine 139 to form γ-H2A.X in response to DNA damage. Therefore, the level of γ-H2A.X is an indicator of DNA damage. Levels of γ-H2A.X were significantly increased in the spinal cords of foetuses with SBA induced by ATRA on E14 (*P* = 0.0174; **[Figure 1](#F1){ref-type="fig"}**), indicating that DNA damage occurred in ATRA-induced SBA embryos. The expression levels of γ-H2A.X were not significantly different compared with the normal controls on E11, E16, and E18 (*P* = 0.9618, 0.6227, and 0.2740, respectively).

![Western blot assay of γ-H2A.X protein expression in SBA embryos and controls.\
(A--D) Western blot results of γ-H2A.X protein expression in individual embryos on E11, E14, E16, and E18. There was a significant difference in the relative protein expression of γ-H2A.X in SBAs and controls on E14. \**P* \< 0.05, *vs*. control. Data are represented as the mean ± SEM (*n* = 3 per group at each time point; Student's *t*-test). MGMT: O6-methylguanine DNA methyltransferase; SBA: spina bifida aperta; E: embryonic day.](NRR-14-361-g004){#F1}

mRNA expression of MGMT in SBA and control embryos {#sec2-8}
--------------------------------------------------

To investigate whether the expression of MGMT is disrupted in embryos with ATRA-induced SBA, MGMT mRNA expression in the spinal cords of E11, E12, E14, E16, and E18 embryos was quantified *via* RT-PCR. In the normal control group, there was a trend of decreased MGMT mRNA expression with increased embryonic days. MGMT mRNA expression was dramatically reduced from E11 to E14 (0.29-fold; *P* = 0.0483), remained essentially stable from E14 to E18, and reached a minimum on E18 (*vs*. E11, 0.46-fold; *P* = 0.0031). Spinal cords from SBA embryos had a statistically significant reduction in MGMT mRNA expression compared with normal controls on E14, E16, and E18.

MGMT mRNA expression was reduced 0.33-fold (*P* = 0.0029) on E14, 0.31-fold (*P* = 0.0425) on E16, and 0.30-fold (*P* = 0.0386) on E18 (**[Figure 2A](#F2){ref-type="fig"}**).

![RT-PCR analysis of the DNA repair gene MGMT.\
(A) Expression profiles of MGMT in normal control (grey, *n* = 5 at each time point) and SBA (black, *n* = 5 at each time point) spinal cords, as detected by RT-PCR. \#*P* \< 0.05, \#\#*P* \< 0.01, *vs*. the E11 control group; &*P* \< 0.05, &&*P* \< 0.01, *vs*. the E12 control group (Student's *t*-test); \**P* \< 0.05, \*\**P* \< 0.01, *vs*. normal control group; Data are shown as the mean ± SEM (*n* = 5 at each time point; one-way analysis of variance followed by Fisher's least significant difference *post hoc* test). (B) RT-PCR analysis of MGMT in normal control, ATRA-treated control and SBAs group on E12 and E18. Data are shown as the mean ± SEM (*n* = 5 at each time point, Student's *t*-test). MGMT: O6-methylguanine DNA methyltransferase; SBA: spina bifida aperta; RT-PCR: real time-polymerase chain reaction; E: embryonic day.](NRR-14-361-g005){#F2}

To investigate whether the reduction of MGMT gene expression is ATRA-dependent, MGMT mRNA expression was analyzed in embryos harvested from ATRA-treated dams that had no abnormal spinal cord phenotype (the ATRA-treated control group). The gene expression of MGMT was compared between the normal control and ATRA-treated control groups, and between ATRA-treated control and SBA groups on E12 and E18. No significant differences in MGMT levels were detected between normal controls and ATRA-treated controls (E12, *P* = 0.8738; E18, *P* = 0.5218), and there was no difference between the ATRA-treated controls and the SBA group (E12, *P* = 0.3736; E18, *P* = 0.4236) (**[Figure 2B](#F2){ref-type="fig"}**). These quantitative RT-PCR results demonstrate that the reduction in MGMT gene expression was not ATRA-dependent, and that downregulation of MGMT was indeed associated with ATRA-induced SBA.

DNA methylation analysis of the MGMT promoter in SBA cases {#sec2-9}
----------------------------------------------------------

We next tested whether DNA methylation affected MGMT gene expression. The promoter CpG island region of the MGMT gene contains 17 CpG sites, as shown in **[Figure 3](#F3){ref-type="fig"}**. To determine the MGMT promoter methylation status, a bisulfite sequencing PCR analysis was performed on a subset of five SBA cases and five controls on E14 and E18. **Figures [4](#F4){ref-type="fig"}** and **[5](#F5){ref-type="fig"}** show the results of the promoter methylation analysis in these two groups on E14 and E18, respectively. We could only detect the methylation levels of 16 CpG sites, because the tenth CpG site was a SNP (rs107272582 C/G) that contained a C to G transversion. MGMT promoter methylation levels in the control and SBA groups were 0.0 ± 0.0% and 0.2638 ± 0.1619%, respectively, on E14 (**[Figure 6A](#F6){ref-type="fig"}**), and 1.000 ± 0.4898% and 1.812 ± 1.009%, respectively, on E18 (**[Figure 6B](#F6){ref-type="fig"}**). On both E14 and E18, MGMT promoter methylation appeared to increase in the SBA group compared with controls; however, no significant difference was found between SBA embryos and controls on E14 or E18 (*P* = 0.18 and *P* = 0.49, respectively).

![Map of the MGMT promoter region.\
This is a sketch map of the CpG site in the promoter region of the MGMT gene. The horizontal line represents the MGMT promoter region, from ch1: 216,161,172- ch1: 216,161,454. Vertical lines represent the CpG sites. Star: SNPs at CpG locations (rs107272582 C/G and rs104902905 C/T, successively). MGMT: O6-methylguanine DNA methyltransferase; SNPs: single nucleotide polymorphisms.](NRR-14-361-g006){#F3}

![Methylation status analysis of the MGMT promoter in SBA and control animals on E14.\
Methylation analysis of the MGMT promoter in E14 spinal cords (*n* = 5) by BSP in normal control and SBA animals. Each of lines represents a single clone. ●: Methylated CpGs; ○: unmethylated CpGs; N: control; S: SBA. MGMT: O6-methylguanine DNA methyltransferase; SBA: spina bifida aperta; BSP: bisulfite sequencing PCR; E: embryonic day.](NRR-14-361-g007){#F4}

![Methylation status analysis of the MGMT promoter in SBA and control animals on E18.\
Methylation analysis of the MGMT promoter in E18 spinal cords (*n* = 5) by BSP in normal control and SBA animals. Each of lines represents a single clone. ●: Methylated CpGs; ○: unmethylated CpGs; N: control; S: SBA. MGMT: O6-methylguanine DNA methyltransferase; SBA: spina bifida aperta; BSP: bisulfite sequencing PCR; E: embryonic day.](NRR-14-361-g008){#F5}

![Methylation levels of the MGMT promoter in the SBA and normal control groups on E14 and E18.\
(A, B) Error bar plot showing mean methylation levels at E14 (A) and E18 (B) in spinal cords (*n* = 5 per group at each time point) between SBA and control groups for MGMT methylation analysis by BSP. The bottom and top of the bar represent the 25^th^ and 75^th^ percentiles (the lower and upper quartiles, respectively), and the band near the middle of the bar represents the 50^th^ percentile (the median). MGMT: O6-methylguanine DNA methyltransferase; SBA: spina bifida aperta; BSP: bisulfite sequencing PCR; E: embryonic day.](NRR-14-361-g009){#F6}

Discussion {#sec1-4}
==========

The aetiologies of human NTDs are complicated and varied (Li et al., 2018). DNA damage is a risk factor for NTDs. In the present study, the expression of γ-H2A.X was increased on E14 in ATRA-treated SBA embryos compared with normal controls, confirming that DNA damage occurred in ATRA-induced SBA embryos.

DNA repair is a direct response to DNA damage. DNA repair genes are known play a role in human NTDs (Olshan et al., 2005; Liu et al., 2012), but little is known about whether DNA repair genes are involved in ATRA-induced rat models of NTDs. DNA repair genes are crucial for proper embryogenesis and central nervous system development. DNA repair pathways in mammalian cells include damage reversal by MGMT, mismatch repair, nucleotide excision repair, base nucleotide repair, and DNA double-strand break repair (Vlachostergios et al., 2009). The proper functioning of DNA repair mechanisms plays a major role in normal cellular activities and embryogenesis by protecting the genome from endogenous metabolites or exogenous agents that can cause DNA damage. In mice in which a DNA repair gene (such as Rad17 or MGMT) has been knocked out, embryonic lethality occurs, demonstrating that DNA repair enzymes are essential for mammalian development (Glassner et al., 1999; Budzowska et al., 2004). In addition, the elevated expression of DNA repair genes in enriched mouse neural crest cells during early embryogenesis may contribute to maintaining DNA integrity (Albino et al., 2011). We established the expression pattern of MGMT in the neural tube development of normal rat embryos. Our results demonstrated that there was a trend towards decreased MGMT expression with increasing embryonic days in the normal control group. MGMT expression was dramatically reduced from E11 to E14 and remained essentially stable from E14 to E18, suggesting that MGMT is overexpressed during the early stages of embryogenesis to reduce any potential genotoxic damage. MGMT is a DNA repair gene that is known to protect DNA from alkylating agents. The methylating agents methylazoxymethanol and nitrogen mustard can seriously interfere with brain neuron development and motor function in *Mgmt^--/--^* mice (Kisby et al., 2009). Some studies have found that epigenetic modification can lead to the loss of MGMT expression in a number of human cancers (Lind et al., 2004; Bugni et al., 2009; Su et al., 2012). In agreement with these previous studies, we found that MGMT mRNA expression was reduced in the SBA group compared with normal controls; moreover, there was a statistically significant difference on E14--E18. Furthermore, no significant differences were detected in MGMT mRNA levels between normal controls and ATRA-treated controls on E12 and E18. These data suggest that the reduction in MGMT mRNA expression is not ATRA-dependent, and downregulation of MGMT is indeed associated with NTDs in the ATRA-induced SBA rat model. Because neural tube closure begins and ends quite early in development, at approximately E9--E12, a perturbation in neural tube or neural crest cells can be considered relevant only if it can be shown to occur at the time of neural tube closure. However, there was no difference between the groups in MGMT expression at E11 and E12. Differences between the groups were discovered at E14--E18, and the findings may thus be associated with NTD progression rather than initiation. If the downregulation of MGMT gene expression is associated with NTD progression, these results may provide new insights for the prognosis and treatment of NTDs. In contrast to the significant decrease in MGMT expression on E14, the level of γ-H2A.X was dramatically increased, indicating that DNA damage occurred on E14 without the repair effects of MGMT. Because MGMT inhibition can induce cell apoptosis (Konduri et al., 2009; Song et al., 2015), and increased cell apoptosis has been found in the neuroepithelial cells of the lumbosacral neural tube of ATRA-induced SBA rats (Wei et al., 2012), we conclude that the downregulation of MGMT may lead to further apoptosis in lesioned areas in SBA rats.

Because both environmental and genetic factors are thought to be involved in the development of SBA, the observed change in MGMT expression might be due to a number of causes, including genetic mutation, promoter hypermethylation, suppressed transcription factors, altered histone methylation and acetylation, or gene silencing via miRNA/siRNA. DNA methylation, which can be viewed as a link between environmental factors and the control of gene expression, is a heritable and reversible epigenetic process that has been linked to NTDs. A previous study has shown that inactivation of the methyltransferase Dnmt3b disturbs genome-wide de novo methylation and causes a variety of developmental defects in mice, including NTDs (Dean et al., 2005). An *in vitro* analysis of cultured chicken embryos demonstrated that disrupted DNA methylation might prevent the proper closure of the neural tube (van der et al., 2008). More recent studies have demonstrated that global DNA hypomethylation (Chen et al., 2010), and hypomethylation of LINE-1 (Wang et al., 2010, 2015), are each related to an increased risk of NTDs. We investigated the methylation status of all CG sites in the MGMT promoter CpG island and examined whether the downregulation of MGMT is determined by promoter DNA methylation. However, there were no significant differences in MGMT promoter methylation between SBA and control embryos. The decreased MGMT observed in ATRA-induced SBA in rats thus cannot be explained by DNA methylation in the promoter region. Some scholars have reported that the overexpression of wild-type P53 *in vivo* can inhibit the transcriptional activity of MGMT (Srivenugopal et al., 2001; Grombacher et al., 1998) without affecting promoter methylation, and ATRA is known to be able to upregulate p53 expression (Lu et al., 2013). These previous findings may explain our results, at least in part. However, the interaction between MGMT and p53 in ATRA-induced SBA in rat embryos requires further exploration. Our results may also be due to the small sample size, which needs to be verified in the future with a larger sample size.

Tran et al. (2012) found that high MGMT expression is associated with NTDs in humans, particularly in female embryos. However, our study showed that MGMT expression is reduced in ATRA-induced SBA in rats. The divergent results may be due to the fact that we are using a non-human animal model of NTD. Further studies are necessary to understand the divergent results of these two studies. Tran et al. (2012) also found that hypomethylation was related to an increased risk for NTDs -- more precisely, for cephalic malformations -- but that in spina bifida cases, the average MGMT methylation level was not significantly different than that in the controls. This finding is consistent with our results.

One limitation in the current study is that we focused on DNA methylation in the MGMT promoter region only. DNA methylation beyond the CpG island could also play a role in gene expression (Edgar et al., 2014), and we may have overlooked CpG sites that fall outside the CpG island. Additionally, recent findings revealed that non-CpG methylation, of CHH and CHG (where H is A, T, or C), could also influence the gene expression of MGMT (Saikia et al., 2017). Apart from changes in DNA methylation, there are many mechanisms for decreased gene expression, including miRNA/siRNA expression and histone modifications. The miR221/222 can act on MGMT, and the downregulation of MGMT is associated with elevated expression of miR221/222 (Quintavalle et al., 2013). The mechanism of reduced MGMT mRNA expression in ATRA-induced SBA requires further exploration. Another limitation of our study is that protein expression and activity of MGMT in ATRA-induced SBAs were not detected. The protein expression and activity of MGMT, and post-translational modifications that may affect MGMT expression in the developing embryo, will be explored in our future research.

To our knowledge, this is the first study to verify that DNA damage occurs in ATRA-induced SBA embryos, indicating that DNA damage and DNA repair responses are involved in SBA in rats. Moreover, this study explored the expression pattern of the DNA repair gene MGMT in neural tube development in normal rat foetuses and established a relationship between MGMT mRNA downregulation and the risk of NTD in ATRA-induced SBA in rat foetuses. The downregulated MGMT might be involved in NTD progression. It is important to determine the effect of MGMT on NTD and to investigate the mechanism of its downregulation for the treatment and prognosis of NTD. However, this downregulation of MGMT is not caused by a change in the methylation level of its promoter. Further studies will continue to investigate the mechanism of MGMT mRNA downregulation in ATRA-induced SBA in rat foetuses.
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